MedPlus Health Services Limited – Investor Presentation Summary
Key Operational Highlights
- Total revenue reached ₹18,796 million for Q1 FY2027 (quarter ended June 30, 2026), representing a 21.8% year-over-year increase from Q1 FY2026 and a 0.8% quarter-over-quarter increase from Q4 FY2026.
- The store network expanded with 222 gross additions and 146 net additions during the quarter, reaching a total of 5,476 stores as of June 30, 2026.
- 125 net additions occurred beyond Tier-One cities, indicating expansion in smaller markets.
- Private label revenue decreased by 1.5% year-over-year.
- Stores operational for more than 12 months showed strong performance with 15.3% revenue growth over Q1 FY2026.
Key drivers of operational performance: Cluster-based network expansion and omni-channel service capabilities.
Segment-wise Performance
- Pharmacy segment revenue: ₹17,810.6 million with Operating EBITDA of ₹588.1 million (3.2% margin)
- Other segments (including Opticals and Diagnostics): ₹304.8 million revenue with Operating EBITDA of ₹65.9 million (17.8% margin)
- Corporate and other adjustments: ₹(2.8) million
Explanation of significant changes in segment performance: The pharmacy segment remains the dominant revenue contributor while other segments show higher profitability margins.
Financial Highlights
Revenue: ₹18,796.0 million
EBITDA: ₹1,530.7 million
PAT: ₹331.7 million
EPS: Not Specified
Margins: Gross Margin 24.5%, Operating EBITDA Margin 3.5%, PAT Margin 1.8%
YoY/QoQ comparison: Revenue increased 21.8% YoY but Operating EBITDA declined 10.6% YoY and 39.5% QoQ
Drivers of financial performance: Lower gross margin percentage (down 160 bps YoY and 200 bps QoQ) and increased expenses (up 19.7% YoY)
Comparison to market estimates: Not Specified
Key Risks: Not explicitly disclosed in the presentation
Geographical Revenue Split
Domestic vs Export/Regional Revenue: Not Specified
Regional Breakdown: Not Specified
Balance Sheet Snapshot
Net Debt/Equity: Not Specified
Reserves: Not Specified
Current Assets/Liabilities: Not Specified
Working Capital/Leverage Metrics: Inventories stood at ₹14,395.6 million; Trade payables at ₹3,595.5 million
Financial Health Insights: Strong cash position of ₹6,218.8 million as of June 30, 2026
Capex & Cash Flow Health
Capital Expenditure: Not Specified for the quarter, but PPE and CWIP increased to ₹3,602.6 million
Free Cash Flow: Not Specified
Operating Cash Flow: ₹1,252 million generated in Q1 FY2027 (192.2% of Operating EBITDA)
Net Debt Movement: Not Specified
Investment Rationale: Focus on cluster-based expansion and omni-channel capabilities
Strategic & R&D Initiatives
Investments in Innovation: Extensive in-house technology platform supporting omni-channel offerings; private label portfolio of 1550+ SKUs
Expected impact on growth: Expansion of target addressable market via omni-channel; increased retention; operational extension of <2 hour delivery to more locations
Strategic Rationale: Growing in cities with market leadership (Metro and Tier-One followed by Tier-Two and beyond); replicating leadership in newer markets; increasing private label contribution in pharma and FMCG products
Industry Trends & Business Environment
Macro/Industry Trends: Not explicitly discussed in the presentation
Impact on Company: Not explicitly discussed in the presentation
Management Commentary & Growth Outlook
Strategic Outlook: Focus on three key pillars: (A) Growth in existing clusters and developing new clusters, (B) Leveraging leadership in omni-channel, (C) Expanding share of private label for higher margins and wallet share
FY Guidance: Not explicitly provided
Market Share Targets: Not explicitly provided
Risks and Opportunities: Not explicitly highlighted